Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer

BACKGROUND. Trastuzumab and pertuzumab are approved for the neoadjuvant treatment of human epidermal growth receptor 2 (HER2)‐positive breast cancer, but cardiac safety data is limited. We report the cardiac safety of dose‐dense doxorubicin and cyclophosphamide (AC) followed by paclitaxel, trastuzum...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Yu, Anthony F., Singh, Jasmeet C., Wang, Rui, Liu, Jennifer E., Eaton, Anne, Oeffinger, Kevin C., Steingart, Richard M., Hudis, Clifford A., Dang, Chau T.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2017
Aiheet:
Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469581/
https://ncbi.nlm.nih.gov/pubmed/28341761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0406
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia